Nrc Health (NRC)
AI stock analysis · as of Jun 11, 2026
Loading microstructure…
NRC Health is a small-cap healthcare experience analytics SaaS provider serving 250+ of the top 400 U.S. health systems, with sticky subscription revenue tied to CMS CAHPS compliance and value-based care. After a brutal Q4 attrition-driven miss, the company has shown operational recovery via large contract wins, AI product (Huey) rollout, and the Nobl acquisition. The core question: can new leadership stabilize churn and reaccelerate growth enough to justify a premium trailing multiple, while fending off Press Ganey and Qualtrics?
valuationFairly valued to modestly expensive: forward P/E of 16.4x and EV/EBITDA of 16x are reasonable for a sticky SaaS model, but P/S of 3.1x, PEG of 1.32 on negative earnings growth (-44%), and 3.1% top-line decline make the price hard to justify without proof of reacceleration.
This analysis is from Jun 11, 2026. Want the latest on NRC, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Sticky subscription base with 250+ of top-400 health systems and top-10 customers growing from 15% to 20% of revenue (2023-2025), signaling successful land-and-expand
- · Regulatory tailwind: CMS value-based purchasing ties hospital reimbursement to CAHPS scores, creating non-discretionary demand for NRC's core survey products
- · Operational turnaround evidence: largest deal in 45 years, major Georgia hospital win, and 62% stock surge over the prior year suggest the post-Q4 attrition crisis is being addressed
- · Strong unit economics: 61.8% gross margin, 16% operating margin, 41.9% ROE, and $15.7M FCF on a $430M market cap (~4.6% FCF yield) plus a 2.8% dividend
- · Forward P/E of 16.4x vs trailing 49x implies the market expects significant earnings normalization; if achieved, multiple compression risk is limited
- · Elevated short interest (16.5% of float, ~4 days to cover) on a thinly-traded name with 49% insider ownership creates squeeze potential on positive surprises
Bear case
- · Revenue declined ~4% YoY in 2025 (to $137.4M from $143.1M) and net income collapsed from $31M (2023) to $11.6M (2025), a 63% drop over two years
- · Earnings growth of -44% with a PEG of 1.32 suggests the stock isn't actually cheap relative to deteriorating fundamentals
- · Competitive squeeze from much larger Press Ganey and Qualtrics with greater R&D budgets; low barriers to entry invite further pricing pressure
- · Existential AI substitution risk — customers may use generative AI tools to replace survey/analytics workflows, and NRC's Huey/Nobl response may be insufficient
- · Balance sheet is thin: $4.1M cash against $79M debt and a 578 debt-to-equity ratio leaves little cushion if attrition recurs
- · Customer concentration risk with top-10 at 20% of revenue; the Q4 attrition event proved this is not theoretical
- · Ukraine-based outsourced development creates ongoing operational/geopolitical exposure
Catalysts
- · July 27, 2026 earnings — will reveal whether large new contract wins translate to revenue reacceleration and churn stabilization
- · Further large contract announcements following the 'biggest deal in 45 years' win, validating commercial momentum
- · AI/Huey product traction metrics or new partnership announcements demonstrating competitive defense against Press Ganey/Qualtrics
- · Potential short squeeze given 16.5% short float and improving operational narrative on any earnings beat
- · M&A optionality — small float, 49% insider ownership, and a strategic asset base could attract acquirer interest
- · Margin recovery as 2024 Nobl integration costs roll off and inflationary pressures normalize
Key risks
- · Further client attrition events similar to the Q4 miss that drove a 27% single-day drop
- · Reduction or elimination of CMS value-based purchasing requirements under federal healthcare policy changes
- · Failure to keep AI capabilities competitive, accelerating churn to Press Ganey/Qualtrics
- · Cybersecurity breach given PHI handling and prior 2020 incident plus 2022 third-party attack
- · Debt service stress if EBITDA continues compressing — leverage is meaningful for a company this size
What to watch
- · July 27, 2026 earnings — revenue trajectory, net retention/attrition commentary, and FY guide
- · Any 8-K announcing additional large contract wins or customer losses
- · Updates on Huey AI engine adoption and Nobl integration progress
- · Short interest trends — currently 16.5% of float with ~4 days to cover
- · Key technical levels: $22.79 52-week high as resistance, $11.01 52-week low as downside risk anchor
- · Insider transactions given the 49% insider ownership concentration
Key metrics
Price target rationale
Base case applies ~18x forward P/E on normalized EPS approaching $1.15-1.20 as new contracts ramp, roughly in line with current EV/EBITDA. Bull case assumes successful churn stabilization and AI-driven reacceleration to ~22x on $1.30 EPS plus short squeeze dynamics. Bear case applies 12x on depressed $1.05 EPS if attrition resumes and competitive pressure intensifies.
On Wall Street's view (mixed): No sell-side coverage is available (analyst_count is null), so there is no consensus target to validate against. Our neutral stance reflects a balance between genuine commercial momentum and unresolved earnings deterioration.
Latest filing (10-K)
NRC Health is a niche but competitively squeezed healthcare experience SaaS company with sticky subscription revenue from 250+ top health systems, a new leadership team betting on AI to fend off much larger rivals Press Ganey and Qualtrics, while regulatory tailwinds from value-based care keep its CAHPS compliance products in demand.
National Research Corporation (NRC Health) is a healthcare analytics and experience management company that has served the healthcare industry for nearly 45 years. It sells subscription-based software and research solutions to hospitals and health systems, helping them measure and improve patient experience, employee engagement, consumer reputation, and market positioning. Revenue is primarily recurring, derived from annual contract renewals supplemented by cross-selling additional solutions to existing customers and adding new clients. The company operates exclusively in healthcare, serving over 250 of the top 400 U.S. health systems by net patient revenue.
What the news says · bullish
NRC Health's dominant storyline is one of operational recovery and business momentum after a painful Q4 2026 earnings miss that sent shares down 27% on high client attrition. Since then, the narrative has shifted positively: the company landed its biggest deal in 45 years, signed a major Georgia hospital system, partnered with the Healthcare Experience Foundation for measurable readmission improvements, and saw a 62% one-year stock surge as of April. The June 11 single-day 8% drop introduces fresh near-term uncertainty and warrants monitoring, but the broader trend of new contract wins and product innovation (AI-driven patient insights) appears intact. Several headlines in the feed reference 'NRC' in the context of nuclear regulatory approvals (Oklo, Nano Nuclear, Hadron Energy) and are unrelated to NRC Health, so the relevant signal set is moderate rather than dense.
This analysis is from Jun 11, 2026. Markets move. Get the current read on NRC and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.